Research Study

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
Principal Investigator 
Anthony Traboulsee

Overview

Body Locations and Systems 
Multiple Sclerosis
ClinicalTrials.gov# 
NCT02545868
Status 
Closed to Recruitment
Study Start/End 
Feb 18, 2016 to Feb 28, 2019
Locations 
UBC Hospital, Vancouver General Hospital
Name/Title 
Michelle K. Wong, Research Coordinator
Phone 
604-822-7949
Email Address 
michelle.w@ubc.ca
Purpose of Study 

This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT], 23-valent pneumococcal polysaccharide vaccine [23-PPV], influenza vaccine, and keyhole limpet hemocyanin [KLH]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.